en · de · es · pt
compound-index.peptides6908.com › Topic › �ˆ†子身份与天然来源 — Worked Examples

�ˆ†子身份与天然来源 — Worked Examples

By Editorial Desk · published 2025-11-28 · last reviewed 2025-12-29 · Topic

合成肽 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

分子身份与天然来源

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

Background, Structure, and Mechanism

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Thymosin-alpha-1 at a glance

PropertyValueNotes
化学分类线性肽由28个氨基酸组成
分子量约3108 Da合成版本一致
外观白色至类白色粉末冻干品
溶解度易溶于水微溶于有机溶剂
储存温度-20°C(冻干)溶解后2-8°C

Research History and Clinical Assessment

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Related pages on this site

Handling, Storage, and Analytical Verification

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

Notes from published material

==== US Federal Trade Commission ==== On 27 February 2019, the United States Federal Trade Commission (FTC) reached a consent decree with ByteDance, fining it US$5.7 million for collecting information from minors under the age of 13 in violation of the Children's Online Privacy Protection Act (COPPA). ByteDance responded by adding a kids-only mode to TikTok which blocks the upload of videos, the building of user profiles, direct messaging, and commenting on others' videos, while still allowing the viewing and recording of content. In May 2020, an advocacy group filed a complaint with the FTC saying that TikTok had violated the terms of the February 2019 consent decree with the FTC, which sparked subsequent congressional calls for a renewed FTC investigation. In March 2022, following a class action lawsuit for violations of COPPA, TikTok settled for US$1.1 million. In March 2024, it was reported that the FTC continues to investigate TikTok. In August 2024, the FTC and US Department of Justice filed a joint lawsuit alleging violations of the 2019 consent decree. In August 2026, TikTok and ByteDance agreed to pay $400 million to settle the lawsuit.

=== Category:EC 1.7 (act on other nitrogenous compounds as donors) === Category:EC 1.7.1 (with NAD+ or NADP+ as acceptor) Category:EC 1.7.2 (with a cytochrome as acceptor) Category:EC 1.7.3 (with oxygen as acceptor) Urate oxidase EC 1.7.3.3 Category:EC 1.7.7 (with an iron–sulfur protein as acceptor) Category:EC 1.7.99 (with other acceptors) Nitrite reductase EC 1.7.99.3 Nitrate reductase EC 1.7.99.4

=== Translation start sites === Using a method developed by Hunt, Shine and Dalgarno showed that the nucleotide tract at the 3' end of E. coli 16S ribosomal RNA (rRNA) (that is, the end where translation begins) is pyrimidine-rich and has the specific sequence 5'-YACCUCCUUA-3'. They proposed that these ribosomal nucleotides recognize the complementary purine-rich sequence 5'-AGGAGGU-3', which is found upstream of the start codon AUG in a number of mRNAs found in viruses that affect E. coli. Many studies have confirmed that base pairing between the Shine–Dalgarno sequence in mRNA and the 3' end of 16S rRNA is of prime importance for initiation of translation by bacterial ribosomes. Given the complementary relationship between rRNA and the Shine–Dalgarno sequence in mRNA, it was proposed that the sequence at the 3'-end of the rRNA determines the capacity of the prokaryotic ribosome to translate a particular gene in an mRNA. Base pairing between the 3'-end of the rRNA and the Shine–Dalgarno sequence in mRNA is a mechanism by which the cell can distinguish between initiator AUGs and internal and/or out-of-frame AUG sequences. The degree of base pairing also plays a role in determining the rate of initiation at different AUG initiator codons.

Sources: en.wikipedia.org

Further detail

MS1 is a positive allosteric modulator (PAM) of the μ-opioid receptor (MOR). It was developed from structural modification of the earlier MOR PAM BMS‐986122. The drug has been found to augment the affinity of the MOR agonist levomethadone ((R)-methadone) for the MOR by 7-fold in vitro and to potentiate activation of the MOR by levomethadone by 4-fold in a G protein assay. However, MS1 displays strong probe dependence, and while it potentiates the MOR agonists levomethadone and morphine, it had no effect on the affinity or potency of the MOR agonists DAMGO or endomorphin-1. MS1 shows a preference for β-arrestin recruitment over G protein activation with endomorphin-1 exposure. The drug's actions are reportedly similar to those of BMS-986122, though its unclear if their mechanisms of action are the same. MS1 shows potentiated analgesic effects with opioids in animals. It also did not worsen opioid withdrawal symptoms, respiratory depression, or analgesic tolerance. MS1 and other atypical MOR activators are of potential interest in the development of novel opioid analgesics with reduced adverse effects and misuse potential. MS1 has notably been found to penetrate the blood–brain barrier in animals. The potential of the related MOR PAMs BMS-986121 and BMS-986122 as pharmaceutical drugs has been restricted owing to their complex chemical synthesis. MS1 has a much simpler synthesis in comparison and hence has been regarded as having overcome this limitation. MS1 was first described in the scientific literature by 2015.

=== Ali El Mansour === Ali El Mansour (Fady Elsayed) is a new trader Adler hired due to his family ties to the Egyptian sovereign wealth fund. To rescue Pierpoint from a fatal debt crisis, Eric reaches out to Ali to have him bring in his family as the firm's buyers. Pierpoint is thereby absorbed into Al-Mi'raj, a holding company for the Egyptian sovereign wealth, who decide to consolidate the firm's trading to the New York headquarters and thereby shut down the London office.

=== Sequencing and synthesis === The sequence of the oligonucleotide selected using SELEX is determined with the help of DNA sequencing. This information is used for the synthesis of the oligonucleotide's enantiomer, the L-RNA aptamer, using L-nucleotides.

Sources: en.wikipedia.org

Frequently asked questions

胸腺素α1是激素吗?

它不是经典的内分泌激素,而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现,而非经血液循环作用于远隔器官。

天然来源是什么?

天然胸腺素α1主要从胸腺组织提取,也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本,不再依赖动物组织。

它和胸腺素组分5有什么关系?

胸腺素组分5是牛胸腺提取物的粗组分,包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽,具有明确的28个氨基酸序列。

What is thymosin alpha-1 derived from?

It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.

Network